SCYNEXIS ended Q1 2026 with $72.4 million in cash — enough runway to mid-2029 — but the number that matters most isn’t on the balance sheet. It’s the $146 million in annual net sales milestones dangling from GSK’s promised relaunch of Brexafemme, a figure SCYNEXIS controls essentially nothing about. That dependency sits at the center of a company now asking investors to hold two very different strategic theses simultaneously: a fungal disease franchise built around second-generation ibrexafungerp, and a pivot into ADPKD via the SCY-770 acquisition from Poxel S.A.
The SCY-770 deal defines SCYNEXIS’s near-term identity more than anything else. The asset is an oral, direct AMPK activator with eight completed clinical trials behind it and FDA Orphan Drug Designation in hand — which means SCYNEXIS didn’t buy a preclinical gamble, it bought a de-risked molecule that Poxel couldn’t finance through to proof-of-concept. The $8 million in-process R&D charge absorbed in Q1 reflects what was essentially a distressed acquisition: real clinical data, limited competition for the asset, and a Phase 2 start planned for Q4 2026 with an efficacy readout in the second half of 2027. For a company with a mid-2029 cash runway, that timeline is tight but executable without requiring another raise before the readout lands.
SCY-247 complicates the narrative without resolving it. Topline IV Phase 1 data arriving in Q3 2026 will tell the market whether the formulation strategy holds, but SCYNEXIS is already threading expanded access for the oral version — a move that generates goodwill and real-world signal without generating revenue. R&D expenses jumped 140% year-over-year to $12.4 million in Q1, almost entirely driven by the SCY-770 accounting charge, so the underlying burn rate on SCY-247 is actually modest. Still, SCYNEXIS openly acknowledges it’s hunting non-dilutive funding for that program, which signals the board has no intention of letting SCY-247 crowd out SCY-770 capital allocation.
The single consequence worth tracking: whether GSK sets a Brexafemme relaunch date before SCYNEXIS’s next financing window opens. That milestone revenue is the only variable that changes SCYNEXIS’s leverage in any future capital raise — without it, the company’s negotiating position stays exactly where it is today.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
